Top

CardioVascular and Interventional Radiology

Published in:

01-06-2011 | Clinical Investigation

Hepatic Arterial Chemoembolization Using Drug-Eluting Beads in Gastrointestinal Neuroendocrine Tumor Metastatic to the Liver

Authors: Shantanu K. Gaur, Jeremy L. Friese, Cheryl A. Sadow, Rajasekhara Ayyagari, Christoph A. Binkert, Matthew P. Schenker, Matthew Kulke, Richard Baum

Published in: CardioVascular and Interventional Radiology | Issue 3/2011

Abstract

Purpose

This study was designed to evaluate short (<3 months) and intermediate-term (>3 months) follow-up in patients with metastatic neuroendocrine tumor to the liver who underwent hepatic arterial chemoembolization with drug-eluting beads at a single institution.

Methods

Institutional review board approval was obtained for this retrospective review. All patients who were treated with 100–300 or 300–500 μm drug-eluting LC Beads (Biocompatibles, UK) preloaded with doxorubicin (range, 50–100 mg) for GI neuroendocrine tumor metastatic to the liver from June 2004 to June 2009 were included. CT and MRI were evaluated for progression using Response Evaluation Criteria In Solid Tumors (RECIST) or European Association for the Study of the Liver (EASL) criteria. Short-term (<3 months) and intermediate-term (>3 months) imaging response was determined and Kaplan–Meier survival curves were plotted.

Results

Thirty-eight drug-eluting bead chemoembolization procedures were performed on 32 hepatic lobes, comprising 21 treatment cycles in 18 patients. All procedures were technically successful with two major complications (biliary injuries). At short-term follow-up (<3 months), 22 of 38 (58%) procedures and 10 of 21 (48%) treatment cycles produced an objective response (OR) with the remainder having stable disease (SD). At intermediate-term follow-up (mean, 445 days; range, 163–1247), 17 of 26 (65%) procedures and 8 of 14 (57%) treatment cycles produced an OR. Probability of progressing was approximately 52% at 1 year with a median time to progression of 419 days.

Conclusions

Drug-eluting bead chemoembolization is a reasonable alternative to hepatic arterial embolization and chemoembolization for the treatment of metastatic neuroendocrine tumor to the liver.

Brown KT, Koh BY, Brody LA et al (1999) Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. J Vasc Interv Radiol 10(4):397–403PubMedCrossRef

Brown DB, Gould JE, Gervais DA et al (2007) Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J Vasc Interv Radiol 18(12):1469–1478PubMedCrossRef

Caplin ME, Buscombe JR, Hilson AJ, Jones AL, Watkinson AF, Burroughs AK (1998) Carcinoid tumour. Lancet 352(9130):799–805PubMedCrossRef

Clouse ME, Perry L, Stuart K, Stokes KR (1994) Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Digestion 55:92–97PubMedCrossRef

de Baere T, Deschamps F, Teriitheau C et al (2008) Transarterial chemoembolization of liver metastases from well-differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results. J Vasc Interv Radiol 19(6):855–861PubMedCrossRef

Demeure MJ, Thompson NW, Hanto DW, Nagorney DM, Yao (2001) Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery 130(4):682–685 (Discussion)

Diaco DS, Hajarizadeh H, Mueller CR, Fletcher WS, Pommier RF, Woltering EA (1995) Treatment of metastatic carcinoid-tumors using multimodality therapy of octreotide acetate intraarterial chemotherapy, and hepatic arterial chemoembolization. Am J Surg 169(5):523–528PubMedCrossRef

Diamandidou E, Ajani JA, Yang DJ et al (1998) Two-phase study of hepatic artery vascular occlusion with microencapsulated cisplatin in patients with liver metastases from neuroendocrine tumors. AJR Am J Roentgenol 170(2):339–344PubMed

Dominguez S, Denys A, Menu Y, Ruszniewski P (1999) Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumours. Ital J Gastroenterol Hepatol 31:S213–S215PubMed

10.

Dominguez S, Denys A, Madeira I et al (2000) Hepatic arterial chemoembolization with streptozotocin in patients with metastatic digestive endocrine tumours. Eur J Gastroenterol Hepatol 12(2):151–157PubMedCrossRef

11.

Drougas JG, Anthony LB, Blair TK et al (1998) Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors. Am J Surg 175(5):408–412PubMedCrossRef

12.

Eriksson BK, Larsson EG, Skogseid BM, Lofberg AM, Lorelius LE, Oberg KE (1998) Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 83(11):2293–2301PubMedCrossRef

13.

Fiorentini G, Aliberti C, Turrisi G et al (2007) Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: results of a phase II clinical study. In Vivo 21(6):1085–1091PubMed

14.

Gates J, Hartnell GG, Stuart KE, Clouse ME (1999) Chemoembolization of hepatic neoplasms: safety, complications, and when to worry. Radiographics 19(2):399–414PubMed

15.

Gupta S, Yao JC, Ahrar K et al (2003) Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the MD Anderson experience. Cancer J 9(4):261–267PubMedCrossRef

16.

Hajarizadeh H, Ivancev K, Mueller CR, Fletcher WS, Woltering EA (1992) Effective palliative treatment of metastatic carcinoid-tumors with intraarterial chemotherapy chemoembolization combined with octreotide acetate. Am J Surg 163(5):479–483PubMedCrossRef

17.

Ho AS, Picus J, Darcy MD et al (2007) Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. AJR Am J Roentgenol 188(5):1201–1207PubMedCrossRef

18.

Kadivar F, Soulen MC (2010) Enhancing ablation: synergies with regional and systemic therapies. J Vasc Interv Radiol 21(8 Suppl):S251–S256PubMedCrossRef

19.

Kim YH, Ajani JA, Carrasco CH et al (1999) Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma. Cancer Invest 17(7):474–478PubMedCrossRef

20.

Kulke M (2005) Advances in the treatment of neuroendocrine tumors. Curr Treat Options Oncol 6(5):397–409PubMedCrossRef

21.

Kulke MH, Mayer RJ (1999) Carcinoid tumors. N Engl J Med 340(11):858–868PubMedCrossRef

22.

Lammer J, Malagari K, Vogl T et al (2009) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33(1):41–52PubMedCrossRef

23.

Lewis AL, Taylor RR, Hall B, Gonzalez MV, Willis SL, Stratford PW (2006) Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolization. J Vasc Interv Radiol 17(8):1335–1343PubMedCrossRef

24.

Loewe C, Schindl M, Cejna M, Niederle B, Lammer J, Thurnher S (2003) Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results. AJR Am J Roentgenol 180(5):1379–1384PubMed

25.

Marlink RG, Lokich JJ, Robins JR, Clouse ME (1990) Hepatic arterial embolization for metastatic hormone-secreting tumors: technique, effectiveness, and complications. Cancer 65(10):2227–2232PubMedCrossRef

26.

Maton PN (1988) The carcinoid syndrome. JAMA 260(11):1602–1605PubMedCrossRef

27.

Modlin IM, Sandor A (1997) An analysis of 8305 cases of carcinoid tumors. Cancer 79(4):813–829PubMedCrossRef

28.

Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D (1992) Streptozocin doxorubicin, streptozocin fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326(8):519–523PubMedCrossRef

29.

Musunuru S, Chen H, Rajpal S et al (2006) Metastatic neuroendocrine hepatic tumors: resection improves survival. Arch Surg 141(10):1000–1004PubMedCrossRef

30.

Ollivier S, Fonck M, Becouarn Y, Brunet R (1998) Dacarbazine, fluorouracil, and leucovorin in patients with advanced neuroendocrine tumors: a phase II trial. Am J Clin Oncol Cancer Clinical Trials 21(3):237–240

31.

Osborne DA, Zervos EE, Strosberg J et al (2006) Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol 13(4):572–581PubMedCrossRef

32.

Rhee TK, Lewandowski RJ, Liu DM et al (2008) Y-90 radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg 247(6):1029–1035PubMedCrossRef

33.

Rinke A, Muller HH, Schade-Brittinger C et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27(28):4656–4663PubMedCrossRef

34.

Rougier P, Mitry E (2000) Chemotherapy in the treatment of neuroendocrine malignant tumors. Digestion 62:73–78PubMedCrossRef

35.

Ruszniewski P, Malka D (2000) Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumors. Digestion 62:79–83PubMedCrossRef

36.

Ruutiainen AT, Soulen MC, Tuite CM et al (2007) Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver. J Vasc Interv Radiol 18(7):847–855PubMedCrossRef

37.

Schnirer II, Yao JC, Ajani JA (2003) Carcinoid: a comprehensive review. Acta Oncologica 42(7):672–692PubMedCrossRef

38.

Therasse E, Breittmayer F, Roche A et al (1993) Transcatheter chemoembolization of progressive carcinoid liver metastasis. Radiology 189(2):541–547PubMed

39.

van der Lely AJ, de Herder WW (2005) Carcinoid syndrome: diagnosis and medical management. Arq Bras Endocrinol Metabol 49(5):850–860PubMedCrossRef

40.

Varela M, Real MI, Burrel M et al (2007) Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46(3):474–481PubMedCrossRef

41.

Venook AP (1999) Embolization and chemoembolization therapy for neuroendocrine tumors. Curr Opin Oncol 11(1):38–41PubMedCrossRef

42.

Yao JC, Hassan M, Phan A et al (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26(18):3063–3072PubMedCrossRef

Title: Hepatic Arterial Chemoembolization Using Drug-Eluting Beads in Gastrointestinal Neuroendocrine Tumor Metastatic to the Liver
Authors: Shantanu K. Gaur
Jeremy L. Friese
Cheryl A. Sadow
Rajasekhara Ayyagari
Christoph A. Binkert
Matthew P. Schenker
Matthew Kulke
Richard Baum
Publication date: 01-06-2011
Publisher: Springer-Verlag
Published in: CardioVascular and Interventional Radiology / Issue 3/2011
Print ISSN: 0174-1551
Electronic ISSN: 1432-086X
DOI: https://doi.org/10.1007/s00270-011-0122-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Hepatic Arterial Chemoembolization Using Drug-Eluting Beads in Gastrointestinal Neuroendocrine Tumor Metastatic to the Liver

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2011

Radiofrequency Ablation of Osteoid Osteoma: Initial Experience with a New Monopolar Ablation Device

Endovascular Management of Complex Renal Artery Aneurysms Using the Multilayer Stent

Stenting of the Lower Gastrointestinal Tract: Current Status

Cone over Guide Wire Technique for Difficult IVC Filter Retrieval

New Coaxial Transseptal Needle for Creation of Atrial Septal Defects in Adult Sheep

Influence of Vessel Size and Tortuosity on In-stent Restenosis After Stent Implantation in the Vertebral Artery Ostium